Christopher Finch

Christopher Finch is currently the VP of Corporate Development & Strategy at Oruka Therapeutics, where Christopher is focused on developing biologics to treat chronic skin diseases like psoriasis. Prior to this, Christopher worked at CRISPR Therapeutics as the Head of Strategy, driving the development of gene-based medicines using CRISPR/Cas9 technology. Christopher also has experience as a Business Analyst at McKinsey & Company. Christopher holds a Master of Philosophy in Plant Sciences from the University of Cambridge and a Bachelor of Arts in Biochemistry & Biophysics from Amherst College.